Medication Guide

Introduction to FLEXISEQ

FLEXISEQ is a novel medical device for the relief of joint pain that has been examined in several phase III trials, across more than 1000 osteoarthritis patients, for up to 12 months.

These showed that:

  • FLEXISEQ was very effective in reducing pain. In a particular study including a comparator arm using oral celecoxib, FLEXISEQ showed superiority to the oral placebo and demonstrated efficacy and response rates comparable to those reported for the celecoxib treatment arm; and
  • FLEXISEQ demonstrated an incidence of minor side effects in approximately 1 in 10 patients which were mainly mild dermal irritations.

The convenient, transdermal mode of dosing and the low incidence of side effects confers advantages over oral painkillers such as the NSAIDs and COX-II inhibitors, where the incidence of side effects, especially after prolonged use, is well-documented.

FLEXISEQ®: Effective Pain Relief

The results of the most recent phase III trials showed that topically applied FLEXISEQ was clinically effective in reducing pain and restoring joint function (mobility).
FLEXISEQ: A well tolerated alternative

  • Adverse drug interactions
    To date, no adverse drug interactions have been reported or demonstrated with FLEXISEQ
  • A medical device with no pharmacological action.
    Experiments with different formulations of FLEXISEQ have shown that the device does not interfere with key enzymatic complexes.
  • A non-systemic product

    Most drug products, no matter what their mode of administration (e.g. oral or topical), will ultimately be absorbed and transported by the bloodstream systemically around the body prior to exerting their effect. Not only does this dilute the effect of the product away from the site where it is needed, but can also deliver the product to parts of the body where it is undesired and may cause harm.

    The Sequessome Technology® at the heart of FLEXISEQ is different.

    Experiments using Sequessome vesicles labelled with a marker molecule (cyclosporine) have shown that after local topical application of the product, the marker molecule was later accumulating in the lymph system and not becoming widely systemically distributed as might be expected with naked cyclosporine. In other trials where Sequessome vesicles have been loaded with other chemicals (e.g. Ketoprofen) serum samples have shown that the chemicals did not enter the blood stream except in tiny quantities that could only just be measured.

Patient Leaflet Form

It is important you read this carefully before using FLEXISEQ.

ccda 200-310 200-125 ccna ccna security 210-260 cisco 300-206 300-209 dumps sscp certification 70-488 dumps 1z0-803 dumps 300-101 dumps sy0-401 pdf 1z0-062 dumps azure 70-533 200-601 imins2 400-351 ccie wireless 300-135 tshoot 2v0-621 dump cisco 300-075 300-085 dump 642-887 spcore pdf 644-906 imtxr ccda 200-310 200-125 ccna ccna security 210-260 cisco 300-206 300-209 dumps sscp certification 70-488 dumps 1z0-803 dumps 300-101 dumps sy0-401 pdf 1z0-062 dumps azure 70-533 200-601 imins2 400-351 ccie wireless 300-135 tshoot 2v0-621 dump cisco 300-075 300-085 dump 642-887 spcore pdf 644-906 imtxr ccda 200-310 200-125 ccna ccna security 210-260 cisco 300-206 300-209 dumps sscp certification 70-488 dumps 1z0-803 dumps 300-101 dumps sy0-401 pdf 1z0-062 dumps azure 70-533 200-601 imins2 400-351 ccie wireless 300-135 tshoot 2v0-621 dump cisco 300-075 300-085 dump 642-887 spcore pdf 644-906 imtxr ccda 200-310 200-125 ccna ccna security 210-260 cisco 300-206 300-209 dumps sscp certification 70-488 dumps 1z0-803 dumps 300-101 dumps sy0-401 pdf 1z0-062 dumps azure 70-533 200-601 imins2 400-351 ccie wireless 300-135 tshoot 2v0-621 dump cisco 300-075 300-085 dump 642-887 spcore pdf 644-906 imtxr cisco 300-075 300-075 dump 300-075 pass4sure ccda 200-310 200-310 desgn pdf 200-310 practice exam 300-075 pdf 300-075 vce 300-075 examcollection 300-075 exam 300-075 ciptv2 book 300-075 ciptv2 dumps ccda 200-310